Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

• Status: Unknown status
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of weekly administered combination of docetaxel/cisplatin and docetaxel/oxaliplatin in chemotherapy-naïve patients with advanced gastric cancer. The primary endpoint will be the response rate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Collaborator: Sanofi
• Treatments: Cisplatin; Docetaxel; Oxaliplatin

Criteria

Inclusion Criteria:

• histologically proven gastric cancer

• aged 75 years or less

• performance status 0 to 2

• no prior chemotherapy

• inoperable, recurrent, or metastatic

• normal marrow, hepatic and renal functions

Exclusion Criteria:

• active infections

• severe co-morbidities

• pregnant or lactating women

• active brain metastasis

• neuropathy of grade 2 or higher